<DOC>
	<DOCNO>NCT00856986</DOCNO>
	<brief_summary>This trial conduct Europe North America . The aim clinical trial ass compare effect insulin detemir combination liraglutide metformin versus liraglutide metformin subject type 2 diabetes . Subjects continue pre-trial metformin treatment trial .</brief_summary>
	<brief_title>The Effect Insulin Detemir Combination With Liraglutide Metformin Compared Liraglutide Metformin Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Subjects diagnose type 2 diabetes , insulin na√Øve treat metformin monotherapy least 3 month prior screen , stable dose least 1500 mg/day metformin ( least 1500 mg/day ) sulfonylurea ( less equal half maximum approve dose ) , stable dose least 3 month prior screen . Previous shortterm insulin treatment connection intercurrent illness allow discretion Investigator HbA1c 7.010.0 % ( inclusive ) subject metformin monotherapy HbA1c 7.08.5 % ( inclusive ) subject metformin combination sulphonylurea Previous treatment insulin ( except shortterm treatment connection intercurrent illness discretion Investigator ) Treatment glucoselowering agent ( ) state inclusion criterion period 3 month prior screen Recurrent major hypoglycaemia hypoglycaemic unawareness judge Investigator Impaired kidney function Impaired liver function Uncontrolled treated/untreated hypertension Cancer clinically significant disease disorder judge Investigator Previous participation runin phase trial . Rescreening allowed History chronic pancreatitis idiopathic pancreatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>